This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shannon, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shannon, M.
Related Collections
Right arrow Emergency Medicine
PEDIATRICS Vol. 112 No. 5 November 2003, pp. 1180-1181

COMMENTARY

The Demise of Ipecac

Michael Shannon, MD, MPH

Program in Medical Toxicology Division of Emergency Medicine Children’s Hospital/Harvard Medical School Boston, MA 02115

Abbreviations: FDA, Food and Drug Administration

The first 20% of the full text of this article appears below.

In 1965, at the urging of 4 organizations (the American Academy of Pediatrics, the American Medical Association, the American Association of Poison Control Centers, and the Food and Drug Administration’s [FDA’s] Medical Advisory Board), the FDA agreed to grant syrup of ipecac over-the-counter status.1,2 Over the previous 12 years, pediatricians and toxicologists were persuaded that the drug was both safe and effective for treatment of childhood poisonings, justifying its unrestricted availability. In 1985, the Academy recommended that ipecac be discussed with and given to parents at the 6-month (infant) visit.3,4 Although the efficacy of ipecac at improving outcome after childhood poisoning had not been rigorously proven and despite reports of failures,5 adverse outcomes,6,7 and even malicious use, the medication became an integral part of pediatric anticipatory guidance. Widespread use of ipecac in poisoned children was strongly advocated both because of its apparent ability to reduce morbidity and because it significantly reduced the need for emergency department referral.8,9 Erroneously, ipecac’s clinical effectiveness . . . [Full Text of this Article]

Address correspondence to Michael Shannon, MD, MPH, The Program in Medical Toxicology, Division of Emergency Medicine, Children’s Hospital/Harvard Medical School, Boston, MA 02115. E-mail: michael.shannon@tch.harvard.edu




This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
N. R. Kelly and S. H. Sanchez
Is Syrup of Ipecac Still for Sale? Comparison of Pharmacies in a Large Urban Area--2003 Versus 2005
Clinical Pediatrics, May 1, 2007; 46(4): 320 - 324.
[Abstract] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
E. A. Clements and J. B. Shaskos
Current Controversies in Gastrointestinal Decontamination
Journal of Pharmacy Practice, June 1, 2005; 18(3): 209 - 220.
[Abstract] [PDF]

Home page
 Arch. Dis. Child.Home page
Journal watch
Arch. Dis. Child., March 1, 2004; 89(3): 291 - 292.
[Full Text] [PDF]

Home page
 JWatch GastroenterologyHome page
Ipecac -- Going, Going, Gone!
Journal Watch Gastroenterology, January 7, 2004; 2004(107): 8 - 8.
[Full Text]

Home page
 JWatch PediatricsHome page
Ipecac -- Going, Going, Gone!
Journal Watch Pediatrics and Adolescent Medicine, November 24, 2003; 2003(1124): 1 - 1.
[Full Text]

Home page
 JWatch GeneralHome page
Ipecac -- Going, Going, Gone!
Journal Watch (General), November 18, 2003; 2003(1118): 4 - 4.
[Full Text]